ObsEva raises $60 million in Series B financing to fund product pipeline

Swiss biopharmaceutical company ObsEva said it has raised $60 million via a Series B equity placing with some big new investors.

The proceeds from the fundraising will be used to finance the company’s product pipeline for women’s reproductive health conditions, entering late-stage clinical trials.

ObsEva chief executive Ernest Loumaye said: “This significant financing and the quality of the investors affirm that ObsEva is leading the field through our development expertise in high-value, oral treatments for preterm labor, infertility and endometriosis. We welcome the new investors and look forward to benefiting from their insights and expertise as we continue our commitment to develop novel drugs addressing women’s reproductive health.”